Previously, neoantigen vaccines were shown to stimulate multifunctional CD4+ T cells to differentiate into CD4+ Th1 cells in preclinical mouse tumor models or clinical trials with limited sample sizes, thereby inducing a prolonged CD8+ T-cell response [61–63]. Here, CD4 is linked to neoplasm.